Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Petosemtamab phase 1/2 dose-escalation and expansion study in advanced solid tumors
2024-513627-16-01Phase 2Authorised
- Sponsor
- Genmab
- Start
- Mar 2018
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label trial of petosemtamab in head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC) and Nonhematologic neoplasms (3 arms), sponsored by Genmab. Primary endpoints: Objective response rate and Safety and tolerability. Planned start Mar 2018; status: authorised.
02
Drugs
petosemtamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-513627-16-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513627-16-01.